Boston-Paris Biotechnology Summit

Genoskin to attend Boston-Paris Biotechnology Summit In order to better serve our American customers, Genoskin plans to set up a production unit in Boston in 2018. Our project has recently been selected by the NETVA program, which helps companies  prepare for this strategic move. In May, we will attend the Boston-Paris Biotechnology Summit, an independent conference supported by a panel of biotech professionals from both sides of the

Read more


Genoskin invited to MEDEF meeting on how CEOs can drive change

Every year, the MEDEF, France’s largest entrepreneurial organisation, sets up local conferences in an attempt to bring companies together under a predefined theme. This year, Genoskin was invited to the 7th Edition of the Entrepreneurial Event (Grande Tribune des Entrepreneurs) to contribute to the discussion on the role of CEOs in driving change. The widely attended conference was headed by Pierre Gataz, the MEDEF’s president (see

Read more


Genoskin launches new website

September 2016. After several months of hard work and dedication, we are thrilled to officially announce the launch of our new website ! We invite you to visit us at We have built our new website with you in mind. The streamlined user interface provides a more interactive experience, allowing our colleagues, partners, clients and prospects to easily find the

Read more


Genoskin is a winner of the 7th edition of the NETVA contest: See you soon in Boston !

The NETVA (New Technology Venture Accelerator) program consists in a preparation and exposure to high-tech US markets for young innovative French companies. It is run by the Office for Science & Technology of the Embassy of France in the United States in three locations: Boston, San Francisco and Washington, DC. Each year, 15 French startups are selected though a national competition

Read more


Genoskin Happy New Year Wishes 2016


Genoskin presents new skin cancer model at Meet2Win

Genoskin launches new OncoSkin® skin cancer model at Meet2Win Genoskin has developed a new skin cancer model for the in vitro study of melanoma. Patients who suffer from this highly dangerous type of skin cancer currently have limited therapeutic options when the cancer reaches metastasis. The OncoSkin® skin cancer model now enables in vitro studies on live melanoma spheroids implanted

Read more